ZA986095B - 6-azauracil derivatives as IL-5 inhibitors. - Google Patents

6-azauracil derivatives as IL-5 inhibitors.

Info

Publication number
ZA986095B
ZA986095B ZA9806095A ZA986095A ZA986095B ZA 986095 B ZA986095 B ZA 986095B ZA 9806095 A ZA9806095 A ZA 9806095A ZA 986095 A ZA986095 A ZA 986095A ZA 986095 B ZA986095 B ZA 986095B
Authority
ZA
South Africa
Prior art keywords
inhibitors
azauracil derivatives
azauracil
derivatives
Prior art date
Application number
ZA9806095A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Jean Pierre Frans Van Wauwe
Gustaaf Maria Boeckx
Gaston Stanislas Marcell Diels
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA986095B publication Critical patent/ZA986095B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0461—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9806095A 1997-07-10 1998-07-09 6-azauracil derivatives as IL-5 inhibitors. ZA986095B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97202117 1997-07-10

Publications (1)

Publication Number Publication Date
ZA986095B true ZA986095B (en) 2000-01-10

Family

ID=8228530

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9806095A ZA986095B (en) 1997-07-10 1998-07-09 6-azauracil derivatives as IL-5 inhibitors.

Country Status (20)

Country Link
US (2) US6743792B2 (id)
EP (1) EP1003729A1 (id)
JP (1) JP2002508001A (id)
KR (1) KR20010012614A (id)
CN (1) CN1261881A (id)
AU (1) AU756637B2 (id)
BR (1) BR9811499A (id)
CA (1) CA2294533A1 (id)
EE (1) EE9900585A (id)
HR (1) HRP990333A2 (id)
HU (1) HUP0002826A3 (id)
ID (1) ID24224A (id)
IL (1) IL133915A0 (id)
NO (1) NO20000094L (id)
NZ (1) NZ501627A (id)
PL (1) PL337875A1 (id)
SK (1) SK180999A3 (id)
TR (1) TR199903249T2 (id)
WO (1) WO1999002504A1 (id)
ZA (1) ZA986095B (id)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987265A1 (en) 1998-09-18 2000-03-22 Janssen Pharmaceutica N.V. Interleukin-5 inhibiting 6-azauracil derivatives
ATE289596T1 (de) 1998-11-23 2005-03-15 Janssen Pharmaceutica Nv Il-5 hemmende 6-azauracilderivate
PL198205B1 (pl) * 1998-12-18 2008-06-30 Janssen Pharmaceutica Nv Inhibitująca IL-5 pochodna 6-azauracylu, jej zastosowanie i sposób wytwarzania, kompozycja farmaceutyczna, sposób znaczenia in vitro receptora i sposób obrazowania in vitro narządu
EA004740B1 (ru) * 1999-08-06 2004-08-26 Янссен Фармацевтика Н.В. Интерлейкин-5 ингибирующие производные 6-азаурацила
US8073380B2 (en) * 2005-12-30 2011-12-06 Nokia Corporation Media content delivery and recording over broadcast network
CN119161311B (zh) * 2024-11-20 2025-02-11 北京纳百生物科技有限公司 一种地克珠利抗原及其合成方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883527A (en) 1973-10-19 1975-05-13 Pfizer Process for preparation of 2-aryl-1,3,4-triazine-3,5(2H,4H)-diones
US4631278A (en) * 1984-08-01 1986-12-23 Janssen Pharmaceutica N.V. Anti-protozoal α-aryl-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)-benzeneacetonitrile derivatives, pharmaceutical compositions, and method of use therefor
GB8602342D0 (en) * 1986-01-30 1986-03-05 Janssen Pharmaceutica Nv 5 6-dihydro-2-(substituted phenyl)-1 2 4-triazine-3 5(2h 4h)-diones
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
EP0476439A1 (de) * 1990-09-18 1992-03-25 Bayer Ag Substituierte 1,2,4-Triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
DE4120138A1 (de) * 1991-06-19 1992-12-24 Bayer Ag Substituierte hexahydro-1,2,4-triazindione, verfahren zu ihrer herstellung, zwischenprodukte dafuer und ihre verwendung
TW263495B (id) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
DE69615601T2 (de) * 1995-04-14 2002-07-11 Takeda Schering-Plough Animal Health K.K., Osaka Verfahren zur Herstellung von Triazinderivate

Also Published As

Publication number Publication date
HUP0002826A3 (en) 2003-01-28
NZ501627A (en) 2002-02-01
US6743792B2 (en) 2004-06-01
IL133915A0 (en) 2001-04-30
CN1261881A (zh) 2000-08-02
AU8441398A (en) 1999-02-08
SK180999A3 (en) 2000-10-09
PL337875A1 (en) 2000-09-11
JP2002508001A (ja) 2002-03-12
ID24224A (id) 2000-07-13
EP1003729A1 (en) 2000-05-31
HUP0002826A2 (hu) 2001-04-28
NO20000094D0 (no) 2000-01-07
AU756637B2 (en) 2003-01-16
TR199903249T2 (xx) 2000-09-21
US6951857B2 (en) 2005-10-04
WO1999002504A1 (en) 1999-01-21
CA2294533A1 (en) 1999-01-21
KR20010012614A (ko) 2001-02-15
NO20000094L (no) 2000-03-08
US20030220331A1 (en) 2003-11-27
HRP990333A2 (en) 2000-04-30
US20020042416A1 (en) 2002-04-11
EE9900585A (et) 2000-08-15
BR9811499A (pt) 2000-09-19

Similar Documents

Publication Publication Date Title
ZA9811599B (en) Ortho-anthranilamide derivatives as anti-coagulants.
ZA99254B (en) Benzosulfone derivatives.
ZA988078B (en) Substituted oxindole derivatives.
ZA982853B (en) Nicotinamide derivatives.
ZA200006577B (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors.
IL141226A0 (en) 1h-imidazopyridine derivatives
PL345540A1 (en) Thiobenzimidazole derivatives
ZA97521B (en) 19-Nor-pregnene derivatives.
GB9910384D0 (en) Alpha-ketoamide derivatives
ZA992191B (en) Piperidine derivatives.
ZA986089B (en) Novel IL-5 inhibiting 6-azauracil derivatives.
ZA991550B (en) Cyclohexanediole derivatives.
EG23802A (en) 2-Phenylpyran-4-one derivatives
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
ZA200101830B (en) Piperidine derivatives.
ZA982436B (en) Thiazolimine derivatives.
ZA979781B (en) Piperidine derivatives.
ZA986095B (en) 6-azauracil derivatives as IL-5 inhibitors.
GB9827729D0 (en) Thieno-indole derivatives
ZA988206B (en) Piperidinylmethyloxazolidinone derivative.
IL143766A0 (en) Il-5 inhibiting 6-azauracil derivatives
CY2322B1 (en) Benzoaeguequinoline derivatives.
ZA971167B (en) Heterocyclyl-ergoline derivatives.
EP1061912A4 (en) PHENANTHROFURANDERIVATE
IL139276A0 (en) Cyclohexenondioxthio chromanoyl derivatives